
A02 Investigating the contribution of RAD51 paralog mutations to cancer development. Robert Baldock, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.

A03, PR01 Cyclin E: Targeting cell cycle dependencies in CCNE1 amplified tumors. Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Ovarian Cancer Research Center, Philadelphia, PA, United States.

A04 Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers. Anniina Farkkila, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

A05 The contribution of pathogenic variants of cancer susceptibility genes for primary ovarian, fallopian tube, and peritoneal cancers in Japanese. Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan.

A06 Cisplatin-induced DNA damage modifies the chromatin landscape of histone H2B monoubiquitination in a p53-dependent manner. Deborah Marsh, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, Nsw, Australia.

A07 53BP1-driven homologous recombination and PARP inhibitor resistance requires intact BRCA1-PALB2 association. Joseph Nacson, Fox Chase Cancer Center, Philadelphia, PA, United States.

A08 A novel system determines the functional significance of ovarian tumor mutations in the homologous recombination gene RAD51C. Meghan Sullivan, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, United States.

A09 Rational combinational therapy with PARP and BRD4 inhibitor in ovarian cancer. Chaoyang Sun, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A10 Fatty acid synthesis inhibitor, Orlistat, potentiates cisplatin-induced toxicity in ovarian cancer cells. Bennett Van Houten, UPMC Hillman Cancer Center, Pittsburgh, PA, United States.

A11, PR02 Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition. Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, NY, United States.

A12 The metabolic stress mediator LKB1 is required for ovarian cancer metastasis. Adrian Buensuceso, The University of Western Ontario, London, ON, Canada.

A13, PR03 Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma. Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada.
**A14** TP53 missense mutations associate with different metabolic pathways. Linda Kelemen, Medical University of South Carolina, Charleston, SC, United States.

**A15** Fatty acid binding protein 4 is indispensable for ovarian cancer metastasis. Abir Mukherjee, University of Chicago, Chicago, IL, United States.

**A16** COL11A1 confers cisplatin resistance through fatty acid oxidation in ovarian cancer cells. Miran Rada, Albany Medical College, Albany, NY, United States.

**A17** NUAK1 acts as a growth suppressor in epithelial ovarian cancer. Trevor Shepherd, Western University, London, ON, Canada.

**A18** Metabolomic analysis of ovarian cancer risk in the Nurses’ Health Studies: Metabolite associations are more pronounced in non-serous tumors. Oana Zeleznik, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States.

**A19**, **PR04** Tumor-derived indoleamine 2,3-dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid-derived suppressor cells in a murine model of ovarian cancer. Adaobi Amobi, Roswell Park Cancer Institute, Buffalo, NY, United States.

**A20** Claudin-4 regulates ovarian tumor cell response to the microenvironment. Heidi Baumgartner, University of Colorado Denver - AMC, Aurora, CO, United States.

**A21** Computational methods and novel *in vitro* model elucidate a therapeutic target against ovarian cancer metastasis. Molly Carroll, University of Wisconsin-Madison, Madison, WI, United States.

**A22** Functional analysis of PGE2 pathway members EP4 and MRP4 in ovarian cancer. Mc Millan Ching, University of Maryland School of Medicine, Baltimore, MD, United States.

**A23** Neupolipin-1 expression on regulatory T cells in ovarian cancer. Anthony Cillo, University of Pittsburgh, Pittsburgh, PA, United States.

**A24** Ovarian cancer cells convert tissue specific normal stromal cells into tumor-promoting carcinoma-associated mesenchymal stem cells through epigenetic reprogramming. Lan Coffman, University of Pittsburgh, Pittsburgh, PA, United States.

**A25** Tissue transglutaminase interacts with Frizzled 7 in ovarian cancer stem cells. Salvatore Condello, Northwestern University, Chicago, IL, United States.

**A26** PTEN and colonization of the ovary in metastasis of fallopian tube-derived ovarian cancer. Matthew Dean, University of Illinois - Chicago, Chicago, IL, United States.

**A27**, **PR05** Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis. Mark Eckert, University of Chicago, Chicago, IL, United States.
Poster Session A  
Monday, October 2, 2017  
6:00 p.m.–8:30 p.m.  
Grand Ballroom 3–4

A28 Beta-escin inhibits ovarian cancer metastasis by targeting the tumor microenvironment. Hilary Kenny, University of Chicago, Chicago, IL, United States.

A29 Effects of lysophosphatidic acid on ovarian cancer metastatic dissemination. Yuliya Klymenko, University of Notre Dame, Notre Dame, IN, United States.

A30 Autotaxin-induced miRNA exportation and associated mechanisms contributing to tumorigenesis and immune modulation. Sudeepti Kuppa, University of Georgia, Athens, GA, United States.

A31 Mutant p53 increases integrin-ECM interactions in early HGSOC. Laura Lecker, Barts Cancer Institute, London, United Kingdom.

A32 Single cell RNAseq analysis of primary tumor and corresponding metastatic lesion in high grade serous ovarian cancer. Annette Lee, Feinstein Institute, Manhasset, NY, United States.

A33 Patient-specific evaluation of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids. Geeta Mehta, University of Michigan, Ann Arbor, MI, United States.

A34 Induction of a novel ETS1/FAK pathway in metastasizing ovarian cancer cells by the omental microenvironment primes them for metastatic colonization. Anirban Mitra, Indiana University, Bloomington, IN, United States.

A35 Ovarian cancer stem cells subvert tumor specific T cells by disrupting T cells metabolic fitness. Feng Qian, Roswell Park Institute, Buffalo, NY, United States.

A36 Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis. Erinn Rankin, Stanford University, Stanford, CA, United States.

A37 Epigenetic modification of ovarian cancer immunogenicity. Pavlina Spiliopoulou, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland.

A38 Modeling ascites-induced changes in peritoneal mechanobiology and ovarian cancer metastatic success. M. Sharon Stack, University of Notre Dame, South Bend, IN, United States.

A39 An integrated molecular and metabolic approach for harnessing early relapse and chemoresistance in ovarian cancer. Marina Bagnoli, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

A40 Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. Prabhakar Bastola, University of Kansas Medical Center, Kansas City, KS, United States.
A41 Ovarian cancer as an infectious disease: Targeting of mitochondrial activity to prevent and treat recurrent ovarian cancer. Martina Bazzaro, University of Minnesota, Minneapolis, MN, United States.

A42 TR3/NR4A1 as a therapeutic target for ovarian cancer. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, Nashville, TN, United States.

A43 Nucleotide excision repair proteins ERCC1 and XPC, and tumor-infiltrating lymphocytes are biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer. Nikola Bowden, University of Newcastle, Newcastle, Australia.

A44 Chemical biology approach to phenotypic intra-tumor heterogeneity as a source of chemotherapy resistance in high-grade serous ovarian cancer. Daria Bulanova, Institute for Molecular Medicine Finland, Helsinki, Finland.

A45 Treatment patterns and outcomes among platinum-refractory/resistant ovarian cancer patients. Jane Chang, Pfizer, New York, NY, United States.

A46 Hsp90 regulates Twist1 expression through STAT3 to induce epithelial-mesenchymal transition in ovarian cancer. Kay Chong, Yale University, New Haven, CT, United States.

A47, PR06 ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Robert Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A48 Cancer-selective targeting of ribosomal biogenesis in ovarian cancer. Robert Cornelison, University of Virginia, Charlottesville, VA, United States.

A49 FAK signaling supports platinum-resistant ovarian cancer stem cells. Carlos Diaz-Osterman, UCSD Moores Cancer Center, La Jolla, CA, United States.

A50 EP4 receptor antagonism in paclitaxel-resistant ovarian clear cell carcinomas. Cong Fan, University of Maryland School of Medicine, Baltimore, MD, United States.

A51 FOXM1 inhibition by thiostrepton synergizes with olaparib by attenuating adaptive response in ovarian cancer cells. Pingping Fang, The University of Kansas Medical Center, Kansas City, KS, United States.

A52 Potassium channel activator Minoxidil (Rogaine) as a novel single-agent or combination therapy in ovarian cancer. Saverio Gentile, Loyola University Chicago, Maywood, IL, United States.

A53 Precision therapeutic targeting of DNA damage repair defects in ovarian cancer through molecular profiling of patient-derived tumor organoids. Sarah Hill, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
A54 Generation and characterization of a novel panel of platinum resistant HGSOC models. Joseph Hoare, Barts Cancer Institute, QMUL, London, United Kingdom.

A55 PR07 Combined MEK and BCL-2/XI inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer. Claudia Iavarone, Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA, United States.

A56 Development of a cloud-based machine learning system (CLOBNET) to predict platinum resistance in high-grade serous ovarian cancer. Veli-Matti Isoviita, University of Helsinki, Helsinki, Finland.

A57 Drug sensitivity and resistance testing (DSRT) of clinically important compounds on primary ovarian cancer cell lines. Katja Kaipio, University of Turku, Department of Pathology and Forensic Medicine, Turku, Finland.

A58 Transcription factor SREBP2 mediates ovarian cancer drug resistance and recurrence. Galina Karashchuk, Department of Pathology, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, United States.

A59 Polyploid embryonic-like cancer stem cells, tumor origin, and therapeutic resistance. Jinsong Liu, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A60 Drug resistance and phenotype of 2D- and 3D-cultured ovarian cancer patient samples. Danielle Llaneza, University of Virginia, Charlottesville, VA, United States.

A61 Ascites-derived and tissue-derived ovarian cancer cell primary 3D cultures aimed for personalized medicine. Yoshiko Nanki, Keio University School of Medicine, Tokyo, Japan.

A62 ALDH1a1 as a target in ovarian cancer stem cells. Nkechiyere Nwani, Northwestern University, Chicago, IL, United States.

A63 Estrogen receptor signaling in fallopian tube epithelia of BRCA mutation carriers. Sophia George, Sylvester Comprehensive Cancer Center, Miami, FL, United States.

A64 Oxidative stress via inhibition of the mitochondrial electron transport and Nrf-2-mediated anti-oxidative response regulate the cytotoxic activity of plumbagin and related compounds. Manish Patankar, UW-Madison, Madison, WI, United States.

A65 Combination of a thioxodihydroquinazolinone compound with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Wei Qian, University of Pittsburgh, Pittsburgh, PA, United States.

A66 The tissue transglutaminase 2–fibronectin protein complex: A new target in ovarian cancer. Livia Sima, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
A67 Effects of the atypical PKC-ι inhibitor ICA-1 on ovarian cancer proliferation and survival. Tracess Smalley, University of South Florida, Tampa, FL, United States.

A68 Stabilization of SNAIL by USP-1 mediates chemoresistance and cell plasticity in epithelial ovarian cancer. Maura Sonego, CRO Aviano, IRCCS, National Cancer Institute, Aviano, PN, Italy.

A69 High-throughput screening of primary ovarian cancer 3D organoids identifies patient-specific sensitivities. Alice Soragni, UCLA, Los Angeles, CA, United States.

A70 Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors. Dana Walsh, Mayo Clinic, Rochester, MN, United States.

A71 Prospective collection and genomic analysis of serial blood and tissue samples from patients with ovarian cancer treated with neoadjuvant chemotherapy. Elizabeth Stover, Dana-Farber Cancer Institute, Boston, MA, United States.

A72 PARP vs PARG: exploring Poly (ADP-ribose) glycohydrolase inhibitors in the context of high grade serous ovarian cancer. Stephen Taylor, Manchester Cancer Research Centre, Manchester, United Kingdom.

A73 Mechanism of tumor suppressor miRNA let-7 downregulation in ovarian cancer: The epithelial-mesenchymal transition factor Snail is associated with stemness and represses let-7. Julia Unternaehrer-Hamm, Loma Linda University, Loma Linda, CA, United States.

A74 Identification of novel targetable resistance mechanisms and candidate clinical response biomarkers in drug-resistant ovarian cancer, following single agent and combination chemotherapy. Aparajitha Vaidyanathan, University of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom.

A75 Applying precision medicine to ovarian cancer: Proof-of-principle for a “molecular second look”. John Martignetti, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

A76 Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemo in newly diagnosed advanced stage ovarian cancer patients. Khursheed Anwer, Celsion Corporation, Lawrenceville, NJ, United States.
**Poster Session B**
Tuesday, October 3, 2017
12:30 p.m.–3:00 p.m.
Grand Ballroom 3–4

**B01 Gene expression network based identification of drugs targeting advanced ovarian cancer.** Sarah Walker, Dana-Farber Cancer Institute, Boston, MA, United States.

**B02 Influence of germline BRCA mutation on response to oral cyclophosphamide in relapsed heavily pre-treated ovarian cancer.** Pavlina Spiliopoulou, Beatson West of Scotland Cancer Centre, Glasgow, Scotland.

**B03 Targeting the KIF11/KIF15/TPX2 axis to develop new therapies for ovarian cancer.** Rebecca Wates, University of Kansas Medical Center, Kansas City, KS, United States.

**B04 The bromodomain inhibitor INCB054329 enhances olaparib response in ovarian cancer cells by reducing homologous recombination efficiency.** Andrew Wilson, Vanderbilt University Medical Center, Nashville, TN, United States.

**B05 Cloning and vulnerability of intrinsically resistant subset of ovarian cancer stem cells.** Jingzhong Xie, University of Houston, Houston, TX, United States.

**B06, PR08 Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer.** Kaiyang Zhang, University of Helsinki, Helsinki, Finland.

**B07 Targeting DAB2IP in ovarian cancer stem cells.** Xingyue Zong, Indiana University, Bloomington, IN, United States.

**B08 Urinary PGE-M levels and risk of ovarian cancer.** Mollie Barnard, Harvard T.H. Chan School of Public Health, Boston, MA, United States.

**B09 IGF axis plays apivotal role in the ovulation-induced malignant transformation of fallopian tube fimbrial epithelial cells.** Tang-Yuan Chu, Department of Obstetrics & Gynecology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Huilen, Taiwan.

**B10, PR09 Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq.** Kevin Elias, Brigham and Women's Hospital, Boston, MA, United States.

**B11 Antibody-conjugated cardiac glycosides: Potent agents for treatment of ovarian cancer.** Manish Patankar, University of Wisconsin - Madison, Madison, WI, United States.

**B12 Differences in neoplastic transformation potential between OSE and FTE.** Sophia George, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, United States.

**B13 Type II diabetes, related traits, and ovarian cancer risk: A Mendelian randomization analysis.** Holly Harris, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

**B14 IGF axis proteins are the main carcinogens in ovulatory follicular fluid: Evidences from a mammary fat pad tumorigenesis model.** Hsuan-Shun Huang, Center of Gynecological Cancers, Dep. of Research, Buddhist Tzu Chi General Hospital, Huilen, Taiwan.
B15 A cancer specific detection of serum CA125 improves differential diagnosis of epithelial ovarian cancer from benign conditions. Kaisa Huhtinen, University of Turku, Turku, Finland.

B16 The effects of estrogen-progestin combined hormone therapy on risk of ovarian cancer. Alice Lee, California State University, Fullerton, Fullerton, CA, United States.

B17 Differential protein expression patterns in vaginal swabs of patients with high-grade serous ovarian cancer. Danielle Llaneza, University of Virginia, Charlottesville, VA, United States.

B18, PR10 Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study. Francesmary Modugno, University of Pittsburgh, Pittsburgh, PA, United States.

B19 Genome-wide association study of cancer antigen 125. Naoko Sasamoto, Brigham and Women's Hospital, Boston, MA, United States.


B21 C-reactive protein and ovarian cancer risk in the Ovarian Cancer Cohort Consortium. Shelley Tworoger, Moffitt Cancer Center, Tampa, FL, United States.

B22 Capturing L1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers as a way to track tumor development. Zhouchunyang Xia, University of British Columbia, Vancouver, BC, Canada.

B23 The evolution of estrogen receptor signaling in the progression of endometriosis to endometriosis-associated ovarian cancer. Michelle Boisen, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.

B24, PR11 The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.


B26 Immune-active microenvironment in SCCOHT: rationale for therapy with immune checkpoint blockade. Elke Van Oudenhove, New York University School of Medicine, New York, NY, United States.

B27 Proteomics identifies CT45 as a mediator of chemosensitivity and immunotherapy target in ovarian cancer. Marion Curtis, University of Chicago, Chicago, IL, United States.
B28 Targeting the tumor associated carbohydrate antigen STn with humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibits ovarian cancer tumor growth in vitro and in vivo. Daniel Dransfield, Siamab Therapeutics, Newton, MA, United States.

B29 Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and non-inflamed ovarian cancer mouse models. Shannon Grabosch, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.

B30 Oncolytic adenovirus infection leads to contact-dependent activation of Natural Killer cells and augments virotherapy effectiveness for ovarian cancer. Elaine Leung, Institute of Cancer Sciences, Glasgow, United Kingdom.

B31 Tumor intrinsic B7-H3 regulates drug resistance, metabolism and pathogenesis in ovarian cancer. Luciana Madeira da Silva, University of South Alabama, Mobile, AL, United States.

B32 Myeloid derived suppressor cell depletion augments antitumor activity in ovarian cancer. Ramandeep Rattan, Henry Ford Hospital, Detroit, MI, United States.

B33 Neo-epitope peptide vaccines and immune checkpoint blockade in a new preclinical ovarian cancer model. Malcolm Ross, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

B34, PR12 Epigenetic reprogramming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T cell receptors. Li Shen, Roswell Park Cancer Institute, Buffalo, NY, United States.

B35 Australian Ovarian Cancer Assortment Trial – Allocating ovarian cancer patients into clinical trials based on molecular profiling. George Au-Yeung, Peter MacCallum Cancer Centre, Melbourne, Australia.

B36 FOXM1 induces DNA replication stress, and its bidirectional gene partner RHNO1 participates in the DNA replication stress response, in high-grade serous ovarian cancer. Carter Barger, University of Nebraska Medical Center, Omaha, NE, United States.


B38 Synergistic effects of SHP2 and PI3K inhibitors in GAB2-overexpressing ovarian cancer. Hiu Wing Cheung, Medical University of South Carolina, Charleston, SC, United States.


B40 High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment. Jun Dai, Medicum, University of Helsinki, Helsinki, Finland.
B41 Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma. Cristabelle Madona de Souza, Kansas University Medical Center, Kansas City, KS, United States.

B42 The cell adhesion molecule, L1CAM, is important for the dissemination and metastasis of fallopian tube precursor lesions. Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Ovarian Cancer Research Center, Philadelphia, PA, United States.

B43 Disruption of the YAP-LATS2 feedback loop switches ovarian cells from YAP-induced senescence to malignant transformation. Chunbo He, University of Nebraska Medical Center, Omaha, NE, United States.

B44 Early loss of monoubiquitylation of H2B alters key metabolic and immune signaling pathways promoting the progression of high-grade serous ovarian cancer. Jagmohan Hooda, University of Pennsylvania, Philadelphia, PA, United States.

B45 Amplification of ADNP and CEP250 promotes poor prognosis in high-grade serous ovarian cancer. Kubra Karagoz, Cancer Institute of New Jersey, New Brunswick, NJ, United States.

B46 DICER1 and FOXL2 mutations correlate with clinicopathologic features of ovarian Sertoli-Leydig cell tumors. Anthony Karnezis, University of British Columbia, Vancouver, BC, Canada.

B47 Rgnef (p190RhoGEF/Arhgef28) loss impairs ovarian tumor metastatic growth. Elizabeth Kleinschmidt, UC San Diego, La Jolla, CA, United States.

B48 Recurrent gene fusions are common in high-grade serous ovarian cancer. Rainer Lehtonen, University of Helsinki, Helsinki, Finland.

B49 The role Of LATS kinases in regulation of CDK4/6 in ovarian cancer. Larisa Litovchick, Virginia Commonwealth University, Richmond, VA, United States.

B50 YAP induces development of mesenchymal subtype of high grade serous ovarian cancer from granulosa cells. Xiangmin Lv, Massachusetts General Hospital, Boston, MA, United States.

B51 Mutant p53-UCHL1 axis regulates proteasome machinery and promotes high-grade serous ovarian cancer progression. Sumegha Mitra, Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, United States.

B52 Multifunctional adipokine Apelin/APJ pathway cell autonomously promotes ovarian cancer tumorigenesis. Deepika Neelakantan, University of Oklahoma HSC, Oklahoma City, OK, United States.

B54, PR13  

*TERT* is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumours. Jessica Pilsworth, University of British Columbia, Vancouver, BC, Canada.

B55  

Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers. Nolan Priedigkeit, University of Pittsburgh, Pittsburgh, PA, United States.

B56  

PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation. Angela Russo, University of Illinois at Chicago, Chicago, IL, United States.

B57  

Adhesion and beyond: CD44 in ovarian cancer spheroids. Joelle Sacks, University of Illinois at Chicago, Chicago, IL, United States.

B58  

Progesterone receptor (PR) isoforms drive distinct cell-cell interactions and gene expression programs in human fallopian tube models of early HGSOC. Megan Seibel, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

B59  

Single-cell sequencing as a prognostic and predictive tool for ovarian cancer therapy. Timothy Starr, University of Minnesota, Minneapolis, MN, United States.

B60  

Systematic approach for identifying and validating novel therapies and targets for ovarian cancer. Alejandro Villar-Prados, UT MD Anderson Cancer Center, Houston, TX, United States.

B61, PR14  

CRISPR/Cas9-mediated *Trp53, Brca1, Brca2, Pten*, and *Nf1* knockout to generate improved murine models of ovarian high grade serous carcinoma. Josephine Walton, The University of Glasgow, Glasgow, United Kingdom.

B62  

DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1. Qi-En Wang, The Ohio State University, Columbus, OH, United States.

B63  

The role of endometrium in endometriosis-associated ovarian cancer. Michael Wilson, Michigan State University, Grand Rapids, MI, United States.

B64  

The novel ZIP4 regulation and its role in cancer stem cell-related activities in ovarian cancer. Yan Xu, Indiana University School of Medicine, Indianapolis, IN, United States.

B65  

Modeling HGSOC using fallopian tube organoid cultures. Shuang Zhang, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, United States.

B66  

miRNA 3'UTR activity driven enrichment of ovarian tumor-initiating cells (TICs) to overcome the barriers of heterogeneity and TIC plasticity. Anil Belur Nagaraj, Case Western Reserve University, Cleveland, OH, United States.

B67  

Anti-tumor effect of black tea pigments, theaflavin-3/3'-gallate against cisplatin-resistant ovarian cancer cells. Yi Chen, Alderson Broaddus University, Philippi, WV, United States.
**Poster Session B**  
**Tuesday, October 3, 2017**  
12:30 p.m.–3:00 p.m.  
Grand Ballroom 3–4

**B68 Adnexal tumors associated with endometriosis: Experience from an academic institution.** Mohamed Desouki, Vanderbilt University School of Medicine, Nashville, TN, United States.

**B69 Intensive daily monitoring to identify onset, severity, and persistence of peripheral neuropathy following initiation of neurotoxic chemotherapy for women newly diagnosed with ovarian cancer.** Heidi Donovan, University of Pittsburgh, Pittsburgh, PA, United States.

**B70 Mathematical model quantifies the effect of novel combination therapies in high-grade serous ovarian cancer.** Sampsa Hautaniemi, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

**B71 New directions in gynecologic cancer research utilizing Text Information Extraction System (TIES) Cancer Research Network.** Faina Linkov, University of Pittsburgh, Pittsburgh, PA, United States.

**B72 Credentialing ERalpha as target in high-grade serous ovarian cancer.** Steffi Oesterreich, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.

**B73 Activin A and activin C have opposing effects on pathways involved in cancer progression in Ovcar3 cells.** Karen Reader, University of Otago, Dunedin, New Zealand.

**B74 Identification of prognostic molecular subtypes of ovarian serous cystadenocarcinoma by isoform-level gene expression analysis.** Arunima Shilpi, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

**B75 Modeling müllerian high-grade serous carcinogenesis using BRCA1 patient-derived induced pluripotent stem cells.** Nur Yucer, Cedars Sinai Medical Center, Los Angeles, CA, United States.

**B76 Oncogenic Kras and Pik3ca can cooperate with inactivation of various tumor suppressor genes to generate high-grade serous carcinomas in the mouse oviduct.** Yali Zhai, University of Michigan, Ann Arbor, MI, United States.

**B77 PAX8 is disseminated in sera of high grade serous ovarian carcinoma: A potential diseasespecific diagnostic biomarker.** Pourya Naderi Yeganeh, University of North Carolina at Charlotte, Charlotte, NC, United States.